Akero Therapeutics, Inc. Akero Therapeutics, Inc.

Akero Therapeutics, Inc.

AKRO

Clasificación en acciones #3736
Akero Therapeutics, Inc. is a biopharmaceutical firm dedicated to addressing... Akero Therapeutics, Inc. is a biopharmaceutical firm dedicated to addressing cardio-metabolic disorders, with a specific focus on nonalcoholic steatohepatitis (NASH). Its primary objective is the creation of therapeutic agents aimed at re-establishing metabolic equilibrium and enhancing overall well-being. The company's flagship investigational drug is efruxifermin (EFX), a synthetic analog of fibroblast growth factor 21. EFX is designed to shield cells from stress and modulate the systemic metabolism of fats, carbohydrates, and proteins throughout the body. This promising compound is currently undergoing evaluation in a Phase 2a clinical investigation, known as the BALANCED study, for individuals diagnosed with biopsy-confirmed NASH. Originally established as Pippin Pharmaceuticals, Inc., the organization rebranded as Akero Therapeutics, Inc. in May 2018. Founded in 2017, Akero Therapeutics maintains its corporate headquarters in South San Francisco, California.
Precio por acción
$54.65
Última sincronización: 2025-12-09
Capitalización bursátil
$4.50B
Cambio (1 día)
0.00%
Cambio (1 año)
1.58%
País
US
Comercio Akero Therapeutics, Inc. (AKRO)

Categoría

Healthcare
Historial de desdoblamientos de acciones de Akero Therapeutics, Inc. (AKRO)
La acción Akero Therapeutics, Inc. (símbolo: AKRO) tuvo un total de 0 desdoblamientos.
El desdoblamiento más reciente ocurrió el Oct 21, 2026.
Una acción AKRO comprada antes de Oct 21, 2026 equivaldría hoy a 0 acciones AKRO.
Lista de desdoblamientos de acciones
Año Desdoblamiento Multiplicador Multiplicador acumulado
Not enough data for the provided dates.
Desdoblamientos de acciones de empresas similares o competidoras
Empresa Número de desdoblamientos de acciones Multiplicador acumulado País
1 x2
US
0 -
US
1 x3
AU
0 -
CH
0 -
NL